HUMA News and Press, Humacyte Inc. From 09/11/23

DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of results from a Food and Drug Administration (FDA)-regul...

2023-09-06 08:32:50 ET Summary Amid an increasingly uncertain macroeconomic forecast and a rapidly heating up political landscape ahead of the '24 presidential race, we revisit one of our most popular Congress-based trading strategies. The "Congress Buys" strategy tracks stock pur...

2023-08-22 03:28:20 ET Summary Humacyte develops regenerative human tissue for various medical uses, with upcoming BLAs and interest from the US military. Their core technology, Human Acellular Vessel (HAV), addresses problems with current standards of care and has low infection a...

-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in Biologics License Application (BLA) planned for fourth quarter 2023- DURHAM, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-...

2023-08-14 12:42:10 ET Humacyte Inc. (HUMA) Q2 2023 Earnings Conference Call August 14, 2023, 8:00 a.m. ET Company Participants Dr. Laura Niklason - President & CEO Dale Sander - CFO & Chief Corporate Development Officer Dr. Heather Prichard - COO Lau...

2023-08-14 12:38:34 ET More on Humacyte Humacyte gains 10% after $160M funding from Oberland Humacyte stock dips after Q4 sees net loss, no grant revenue Humacyte plunges as Piper downgrades citing further weakness ahead Humacyte to provide Ukraine hospitals ...

2023-08-14 11:33:46 ET Humacyte press release ( NASDAQ: HUMA ): Q2 GAAP EPS of -$0.22. The Company reported cash and cash equivalents of $114.6 million as of June 30, 2023. For further details see: Humacyte GAAP EPS of -$0.22

– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line Results on Track for Q3 2023 – – Results from Vascular Trauma Humanitarian Program in Ukraine Highlighted at 2023 Military Health System Research Symposium ...

DURHAM, N.C., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the second quarter ended June 30, 2023, on Monda...

Results published in Journal of Vascular Surgery – Vascular Science DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, a...